Introgen gets positive Phase III Advexin data

Introgen Therapeutics announced that a preliminary analysis of a late-stage trial of Advexin confirmed their mid-stage efficacy data for patients with recurrent head and neck cancer. And researchers added that a biomarker for the gene target is predictive for identifying patients likely to respond to the therapy. Austin-based Introgen says it will file for approval in U.S. and Europe this quarter.

"Advexin provides therapeutic benefit by restoring p53 tumor suppressor function which is blocked in the majority of head and neck cancers," said Robert E. Sobol, senior vice president, medical and scientific affairs.

- check out the release
- read the report from BioWorld

Related Articles:
Introgen reports biomarker link to new therapy. Introgen report
Introgen touts cancer data. Introgen report

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.